Dendritic cells are the most potent immune cell capable of activating T cells. T cells are the effectors of the immune system and in the present case are the cells that are involved in killing survivin-expressing tumor cells. The cancer marker survivin appears to be present on most of the major cancers but not on non-malignant tissues.
The Company has previously designed dendritic cells for treatment of breast cancer utlizing a process called gene silencing. The current work capitalized on lessons learned in developing DCellVax[1], as well as novel findings regarding utilizing of exosomes, naturally occurring nanoparticles with ability to modulate the immune system.
'The field of immunotherapy is expanding at an unprecedented rate and this is exemplified by the astronomical rise in the use of immunotherapeutic drugs, which now are believed to possess a 100 billion global annual market[2],' said
About
Disclaimer
This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
[1] Regen BioPharma Completes Preclinical Experiments For dCellVax Breast Cancer Immune Therapy |
[2] Cancer Immunotherapy Market Size & Share Report, 2030 (grandviewresearch.com)
Contact:
Chairman & Chief Executive Officer
T: +1-619-722-5505
FAX: +1-619-330-2328
E: david.koos@regenbiopharmainc.com
(C) 2023 Electronic News Publishing, source